BLA 761433 · Janssen Biotech
Rybrevant Faspro
Amivantamab and Hyaluronidase-Lpuj · Endoglycosidase
Priority reviewLast checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 17, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
52
8 Phase 3, 19 recruiting
FAERS reports
306
207 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2026.
RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1.1 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1.3 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1.4 ) as a single agent for the treatment of adult patients with recurrent or metastatic HNSCC whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with OPSCC that is HPV-associated (i.e., by p16 IHC). ( 1.5 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 ) 1.1 First-Line Treatment of NSCLC with...
Mechanism: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies, amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 5, 2026 Supplement 2 · Efficacy · priority review LabelLetter
- Dec 17, 2025 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabel
2 products under this application
- RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 14ML · INJECTION, · Prescription
- RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 10ML · INJECTION, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amivantamab" as an intervention, any sponsor and status, largest first.
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04487080 · 1,074 participants · Start Sep 30, 2020 · Primary completion Aug 11, 2023
Drug: Amivantamab; Osimertinib and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Goodyear, Arizona; Yuma, Arizona; Long Beach, California · 269 sites in all
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Recruiting
Vall d'Hebron Institute of OncologyAcademic, hospital or other
NCT03767075 · 1,000 participants (planned) · Start Dec 10, 2018 · Primary completion May 2027
Drug: Atezolizumab; Futibatinib and 1 more · For: Advanced Solid Tumor
Sites: Villejuif, France; Heidelberg, Germany; Dresden, Germany · 8 sites in all
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06662786 · 1,000 participants (planned) · Start Oct 18, 2024 · Primary completion Dec 15, 2028
Drug: Amivantamab; Cetuximab and 4 more · For: Colorectal Neoplasms
Sites: Gilbert, Arizona; Jonesboro, Arkansas; Springdale, Arkansas · 239 sites in all
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailurePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04988295 · 776 participants · Start Nov 17, 2021 · Primary completion Jul 10, 2023
Drug: Lazertinib; Amivantamab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Mobile, Alabama; Tucson, Arizona; Duarte, California · 249 sites in all
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02609776 · 751 participants · Start May 24, 2016 · Primary completion Dec 31, 2026
Drug: Amivantamab; Amivantamab and 3 more · For: Non-Small-Cell Lung Cancer
Sites: Duarte, California; La Jolla, California; Orange, California · 69 sites in all
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04077463 · 701 participants · Start Sep 4, 2019 · Primary completion Feb 12, 2027
Drug: Lazertinib; Amivantamab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Los Angeles, California; Orange, California; San Francisco, California · 78 sites in all
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06750094 · 700 participants (planned) · Start Dec 12, 2024 · Primary completion Dec 15, 2027
Drug: Amivantamab; Cetuximab and 4 more · For: Colorectal Neoplasms
Sites: Chandler, Arizona; Gilbert, Arizona; Prescott, Arizona · 251 sites in all
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07100080 · 661 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 15, 2028
Drug: Iza-bren; Carboplatin and 3 more · For: Non-Small Cell Lung Cancer
Sites: Irvine, California; Orange, California; Edwards, Colorado · 187 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash47
- infusion related reaction32
- paronychia29
- off label use22
- nausea17
- stomatitis17
- pyrexia14
- administration related reaction13
- decreased appetite13
- pruritus12
- cytopenia11
- fatigue11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 305 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, et al. · Ann Oncol 2024 · Clinical Trial, Phase III
- Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Yang JC, Lu S, Hayashi H, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Leighl NB, Akamatsu H, Lim SM, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K, Haura EB, Leighl NB, et al. · J Clin Oncol 2021 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.